IBO SEC Filings: 8-K, 10-Q, S-3 & 424B – Impact BioMedical

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Impact Biomedical and Zoar Limited Announce SEC Effectiveness of Form F-4 and Schedule Stockholder Meeting for Business Combination

Nov 3, 2026

8-K

Impact BioMedical Inc. Effects 1-for-12.62 Reverse Stock Split

Oct 9, 2026

8-K

Impact Biomedical Announces Filing of Form F-4 Registration Statement for Proposed Business Combination with Zoar Limited

Sep 16, 2026

8-K

Impact Biomedical Inc. Announces 1-for-12.62 Reverse Stock Split to Advance Merger with Zoar Limited

Sep 14, 2026

8-K

Impact BioMedical Amends Merger Agreement, Extends End Date, and Details Share Issuances to DSS, Inc.

Mar 4, 2026

8-K

Impact Biomedical Inc. 2025 Annual Meeting Results: Directors Elected, Auditor Ratified, Executive Compensation Approved

Nov 6, 2025

Prospectus

TYPE

HEADLINE

FILED AT

425

Form 425 - Prospectuses and communications, business combinations

Nov 3, 2026

425

Form 425 - Prospectuses and communications, business combinations

Sep 16, 2026

425

Form 425 - Prospectuses and communications, business combinations

Sep 14, 2026

424B4

OFFERING | Shares amount: 1,500,000 | Share price: $3.00 | Offering amount: $4,500,000.00

Sep 17, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Apr 22, 2026

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Apr 6, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 24, 2025

S-1/A

2,975.00 EFFECTIVE, DATED 2024-09-13

Aug 27, 2024

8-A12B/A

Common Stock, par value $0.01 per share

Aug 23, 2024

S-1/A

1,500,000 Shares EFFECTIVE, DATED 2024-09-13

Aug 20, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFM14A

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Oct 26, 2026

DEF 14C

Form DEF 14C - Other definitive information statements

Dec 30, 2025

PRE 14C

Form PRE 14C - Other preliminary information statements

Dec 11, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Sep 22, 2025

DEF 14C

Form DEF 14C - Other definitive information statements

Sep 9, 2025

PRE 14C

Form PRE 14C - Other preliminary information statements

Aug 26, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Mar 10, 2025

CORRESP

Form CORRESP - Correspondence

Mar 7, 2025

LETTER

Form UPLOAD - SEC-generated letter

Feb 6, 2025

CORRESP

Form CORRESP - Correspondence

Jan 10, 2025

LETTER

Form UPLOAD - SEC-generated letter

Dec 20, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 16, 2024

Impact BioMedical Inc. IBO · SEC Filings